Tudor Investment Corp ET AL Has $5.83 Million Position in Evolent Health, Inc $EVH
by Danessa Lincoln · The Markets DailyTudor Investment Corp ET AL increased its stake in shares of Evolent Health, Inc (NYSE:EVH – Free Report) by 174.4% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 689,262 shares of the technology company’s stock after purchasing an additional 438,095 shares during the quarter. Tudor Investment Corp ET AL’s holdings in Evolent Health were worth $5,831,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Evolent Health by 0.4% during the 3rd quarter. Vanguard Group Inc. now owns 10,966,830 shares of the technology company’s stock worth $92,779,000 after purchasing an additional 45,299 shares in the last quarter. Durable Capital Partners LP acquired a new position in Evolent Health during the 2nd quarter worth approximately $72,326,000. Eventide Asset Management LLC increased its position in Evolent Health by 54.0% during the 3rd quarter. Eventide Asset Management LLC now owns 6,292,511 shares of the technology company’s stock worth $53,246,000 after purchasing an additional 2,205,659 shares in the last quarter. Engaged Capital LLC increased its position in Evolent Health by 13.0% during the 2nd quarter. Engaged Capital LLC now owns 5,854,468 shares of the technology company’s stock worth $65,921,000 after purchasing an additional 675,000 shares in the last quarter. Finally, Rubicon Founders LLC acquired a new position in Evolent Health during the 3rd quarter worth approximately $49,204,000.
Evolent Health Trading Up 1.0%
Shares of NYSE EVH opened at $2.57 on Thursday. The company has a debt-to-equity ratio of 2.34, a quick ratio of 1.31 and a current ratio of 1.31. Evolent Health, Inc has a 52-week low of $2.10 and a 52-week high of $12.06. The firm has a 50 day moving average price of $2.81 and a two-hundred day moving average price of $4.50. The stock has a market cap of $286.36 million, a P/E ratio of -0.50 and a beta of 0.37.
Evolent Health (NYSE:EVH – Get Free Report) last announced its quarterly earnings results on Tuesday, February 24th. The technology company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.06 by $0.02. Evolent Health had a negative net margin of 28.49% and a positive return on equity of 1.49%. The firm had revenue of $468.72 million during the quarter, compared to analysts’ expectations of $468.48 million. During the same period in the prior year, the company posted ($0.02) EPS. The company’s revenue was down 27.5% on a year-over-year basis. As a group, equities analysts forecast that Evolent Health, Inc will post 0.08 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms recently issued reports on EVH. Wall Street Zen upgraded shares of Evolent Health from a “sell” rating to a “hold” rating in a research report on Saturday, February 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Evolent Health in a research report on Friday, March 27th. UBS Group lowered their price objective on shares of Evolent Health from $10.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, February 26th. Truist Financial lowered their price objective on shares of Evolent Health from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, February 25th. Finally, Citizens Jmp lowered their price objective on shares of Evolent Health from $11.00 to $10.00 and set a “market outperform” rating for the company in a research report on Tuesday, January 6th. Thirteen investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Evolent Health presently has an average rating of “Moderate Buy” and a consensus price target of $6.04.
Check Out Our Latest Report on Evolent Health
Evolent Health Profile
Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.
The company’s core offerings include care management solutions, population health analytics and clinical advisory services.
Further Reading
Want to see what other hedge funds are holding EVH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Evolent Health, Inc (NYSE:EVH – Free Report).